CLINICAL_TRIALS
trial_result
· 2011-08-03
Clinical Trial Update: Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines [Phase 2]
Summary
This Phase 2 trial conducted by Merz Pharmaceuticals identified the optimal dose of NT 201 for treating glabellar frown lines.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merz Pharmaceuticals GmbH | Conditions: Glabellar Frown Lines | Phase 2 | Status: COMPLETED